Skip to Main Content

ALS has proven stubbornly resistant to medicinal breakthroughs, with just one new drug securing U.S. approval in the last 22 years. Cytokinetics (CYTK) hopes to change that with the readout of a large clinical trial within the next two weeks.

Success will require beating long odds. Here are seven things you need to know about Cytokinetics and its experimental ALS drug tirasemtiv before the clinical trial results are announced.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.